$0.41
11.61% yesterday
Nasdaq, Jun 05, 10:16 pm CET
ISIN
US15117F3029
Symbol
CLRB
Sector
Industry

Cellectar BioSciences, Inc. Stock price

$0.41
+0.14 53.36% 1M
-0.95 69.99% 6M
+0.11 36.49% YTD
-2.70 86.88% 1Y
-10.99 96.42% 5Y
-2,720.69 99.99% 10Y
-7,496,999.59 100.00% 20Y
Nasdaq, Closing price Thu, Jun 05 2025
-0.05 11.61%
ISIN
US15117F3029
Symbol
CLRB
Sector
Industry

Key metrics

Market capitalization $21.28m
Enterprise Value $7.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.21
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-46.18m
Free Cash Flow (TTM) Free Cash Flow $-43.60m
Cash position $13.91m
EPS (TTM) EPS $-0.53
P/E forward negative
Short interest 5.21%
Show more

Is Cellectar BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Cellectar BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Cellectar BioSciences, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Cellectar BioSciences, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Cellectar BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
74% 74%
-
- Research and Development Expense 22 22
22% 22%
-
-46 -46
9% 9%
-
- Depreciation and Amortization 0.26 0.26
8% 8%
-
EBIT (Operating Income) EBIT -46 -46
9% 9%
-
Net Profit -25 -25
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cellectar BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectar BioSciences, Inc. Stock News

Neutral
GlobeNewsWire
about 11 hours ago
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The c...
Neutral
GlobeNewsWire
one day ago
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical b...
Neutral
Seeking Alpha
23 days ago
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time al...
More Cellectar BioSciences, Inc. News

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Head office United States
CEO James Caruso
Employees 11
Founded 1996
Website www.cellectar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today